NeuroTherapia Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NeuroTherapia's estimated annual revenue is currently $502.5k per year.(i)
  • NeuroTherapia's estimated revenue per employee is $100,500

Employee Data

  • NeuroTherapia has 5 Employees.(i)
  • NeuroTherapia grew their employee count by -17% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.5M5-17%N/AN/A
#2
$8.4M428%N/AN/A
#3
$12.9M640%N/AN/A
#4
$3.6M18-25%N/AN/A
#5
$1090M58388%$38.4MN/A
#6
$5.8M29-3%N/AN/A
#7
$0.8M8-27%$20.7MN/A
#8
$13.7M686%N/AN/A
#9
$0.8M860%$67.6MN/A
#10
$25.9M129-21%N/AN/A
Add Company

NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and are initiating Phase I clinical trials of NTRX-07 in humans in 2019.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$502.5k

Revenue (est)

-17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NeuroTherapia's People

NameTitleEmail/Phone
1
Founder & Chief Medical OfficerReveal Email/Phone
2
PreclinicalReveal Email/Phone
3
President and CEOReveal Email/Phone
Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.8M50%N/A
#2
$0.1M5-37%$4M
#3
$0.4M50%N/A
#4
$0.4M567%N/A
#5
$0.4M50%N/A